Impact of timing of adjuvant chemothapy for early breast cancer: the Royal Marsden Hospital experience.

ABSTRACT:

Background

The optimal time to deliver adjuvant chemotherapy has not been defined.

Methods

A retrospective study of consecutive patients receiving adjuvant anthracycline and/or taxane 1993-2010. Primary endpoint included 5-year disease-free survival (DFS) in patients commencing chemotherapy <31 versus ≥31 days after surgery. Secondary endpoints included 5-year overall survival (OS) and sub-group analysis by receptor status.

Results

We identified 2003 eligible patients: 1102 commenced chemotherapy <31 days and 901 ≥31 days after surgery. After a median follow-up of 115 months, there was no difference in 5-year DFS rate with chemotherapy <31 compared to ≥31 days after surgery in the overall population (81 versus 82% hazard ratio (HR) 1.15, 95% confidence interval (95% C

SUBMITTER: Okines AFC 

PROVIDER: S-EPMC8292350 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature